Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years.

@article{Hughes1994MotorRT,
  title={Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years.},
  author={Andrew J. Hughes and J. P. Frankel and P. A. Kempster and Gerald M. Stern and Andrew John Lees},
  journal={Journal of Neurology, Neurosurgery \& Psychiatry},
  year={1994},
  volume={57},
  pages={430 - 434}
}
To clarify the way in which the clinical response to levodopa changes with the progression of Parkinson's disease, a longitudinal study was performed to quantify motor response characteristics to single doses of levodopa by mouth over three years in 23 patients with fluctuating motor function. A significant increase in motor disability in "on" (time of peak motor improvement) and "off" (before levodopa dose) phases occurred and "on" phase dyskinesia increased by 24%, though the amplitude of… Expand
Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease
TLDR
Comparison of test‐dose and pretreatment scores suggested that a substantial long‐duration response to levodopa remains after many years of treatment, and that lateralized motor deficits show a stronger long duration response than midline ones. Expand
Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease
TLDR
The rate of motor response to oral levodopa may reflect the rate of dopamine interaction with the postsynaptic receptors, providing an indirect objective index of presynaptic dopaminergic homeostasis. Expand
Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
TLDR
The progressive shortening of motor response after both apomorphine and levodopa suggests that pharmacodynamic factors play an important part in determining the duration of motorresponse and argues against altered central pharmacokinetics of levodOPA being principally responsible for the on-off effect. Expand
Evolution of motor fluctuations in Parkinson's disease: A longitudinal study over 6 years
A prospective longitudinal 6‐year study of 34 patients with Parkinson's disease from the time of initiation of drug treatment explored changes in the motor response to L‐dopa over the early to midExpand
Patterns of levodopa response in Parkinson's disease: a clinico-pathological study.
TLDR
Irrespective of the pattern of levodopa response, patients reach a common pathological endpoint at a similar age, and the duration and manifestations of end-stage disease are alike, suggesting a non-linear or exponential time relationship may govern the late clinical and pathological progression of Parkinson's disease. Expand
The response to levodopa in parkinson's disease: Imposing pharmacological law and order
TLDR
Pharmacodynamic modeling of the short‐duration response indicates that with time, the response becomes less graded and small changes in levodopa concentrations can produce big changes in response. Expand
When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease?
TLDR
Evidence is reviewed that suggests that even patients who are apparently still in the honeymoon phase of drug treatment may have early fluctuations in their motor response to dopaminergic therapy, which has important consequences for the long-term outcome and for the medication regimens to be used. Expand
[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
TLDR
The absence of a significant correlation between the early decay of levodopa response and DA terminal density suggests that DA terminal loss alone cannot account for the development of motor fluctuations. Expand
Loss of long-duration response to levodopa over time in PD
TLDR
Modifications of the long-duration response to levodopa may have a pivotal role in generating a fluctuating response, and it is suggested that therapeutic strategies based on maintenance of theLongduration response should be sought to avoid the appearance of motor fluctuations. Expand
Clinical–Pathological study of levodopa complications
TLDR
It is concluded that levodopa benefit declined and adverse effects increased with time and dyskinesia was the earliest and the most common isolated adverse effect. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 16 REFERENCES
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease
TLDR
Although symptom duration was the best predictor of the severity of untreated parkinsonism, levodopa dose correlated best with response half‐time, and may provide a quantitative index of central mechanisms that favor the development of the wearing‐off and on‐off phemonena. Expand
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.
TLDR
It is proposed that the duration of response is primarily determined by levodopa peripheral pharmacokinetics rather than by central pharmacodynamic factors associated with dopamine storage capacity. Expand
Does ageing aggravate parkinsonian disability?
TLDR
It is suggested that age of onset mainly affects the response to levodopa therapy, because it may increase the prevalence of non-dopaminergic lesions of the brain, including those responsible for gait disorders. Expand
Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease
  • M. Hoehn
  • Medicine
  • Acta neurologica Scandinavica
  • 1985
TLDR
Supplemental bromocriptine produced a smoother therapeutic response and decreased “off” period dystonia and leg pains in over 70% of patients, but at dosages below 20 mg daily, it was not particularly effective in severely affected disabled patients. Expand
Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study.
TLDR
It is proposed that bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness are closely related, and that impairment of dopaminergic systems may be involved in both. Expand
The impact of treatment with levodopa on Parkinson's disease.
TLDR
The progress of 178 patients with Parkinson's disease who began treatment with levodopa between November 1969 and December 1972 is reviewed after six years, and 32 per cent of the patients had unequivocal dementia. Expand
Does long‐term aggravation of Parkinson's disease result from nondopaminergic lesions?
TLDR
The motor score with and without levodopa was estimated in parkinsonian patients with variable length of evolution and it is suggested that aggravation of Parkinson's disease mainly results from increasing severity of cerebral nondopaminergic lesions. Expand
TREATMENT OF PARKINSONISM WITH L‐DOPA
TLDR
Significantly better results on L-dopa were achieved for hypokinesia, rigidity, speed of movements, dysarthria and amimia, as did tests for speed and co-ordination, and tests for the activities of daily living showed a much greater improvement in the L- dopa group. Expand
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
TLDR
The pathological findings in 100 patients diagnosed prospectively by a group of consultant neurologists as having idiopathic Parkinson's disease are reported, and these observations call into question current concepts of Parkinson's Disease as a single distinct morbid entity. Expand
Accuracy of clinical diagnosis of idiopathic Parkinson ' s disease : a clinicopathological study of 100 cases
  • J Neurol Neurosurg Psychiatry
  • 1992
...
1
2
...